Back

A biomarker catalog for inflammatory bowel disease medications

Hart, T.; West, K.; Preto, A. J.; Domingo-Fernandez, D.

2025-10-24 health informatics
10.1101/2025.10.22.25338516 medRxiv
Show abstract

IntroductionInflammatory bowel disease (IBD), which includes Crohns disease (CD) and ulcerative colitis (UC), is a multifaceted illness with diverse manifestations. Current treatment strategies are inadequate, with low response rates, secondary loss of response, and serious side effects. MethodsWe leveraged a large multiomics dataset (SPARC IBD) to compile a catalog of biomarkers for (i) disease severity, (ii) medication use, and (iii) response to a medication. Data were stratified based on IBD subtype (UC and CD) and tissue type; biomarker associations were identified using mixed-effects models to account for multiple medication groups, disease status (e.g., remission, active, etc.), and repeated sampling. ResultsOur catalog lists thousands of potential biomarkers for disease severity (9,657), medication effect (293), and medication response (59). These biomarkers, both known and novel, span multiple diagnoses, tissues, and medications. ConclusionThese therapy-specific signatures will enable tracking of treatment response, diagnosis of disease severity, and identification of new therapeutic targets.

Matching journals

The top 10 journals account for 50% of the predicted probability mass.

50% of probability mass above

"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.